Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasmin H Karimi

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancers|July 29, 2025
Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Jonathan Weiss, Shannon A Carty, Yasmin H Karimi
JCO Clinical Cancer Informatics|October 12, 2021
Reply to Ritzwoller et alYasmin H Karimi, Allison W Kurian, Douglas W Blayney, et al.
Annals of Hematology|June 9, 2023
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphomaVictoria R Nachar, Anthony J Perissinotti, Bernard L Marini, et al.
JCO Clinical Cancer Informatics|April 30, 2021
Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record DataYasmin H Karimi, Douglas W Blayney, Allison W Kurian, et al.
Leukemia & Lymphoma|June 9, 2025
Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphomaMeng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips, et al.
Blood Advances|April 4, 2023
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphomaTycel J Phillips, David Bond, Radihka Takiar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative AnalysisJavier Munoz, Allison Rosenthal, Andrew Ip, et al.
Blood|January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialJoshua D Brody, Judit Jørgensen, David Belada, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancers|July 29, 2025
Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Jonathan Weiss, Shannon A Carty, Yasmin H Karimi
JCO Clinical Cancer Informatics|October 12, 2021
Reply to Ritzwoller et alYasmin H Karimi, Allison W Kurian, Douglas W Blayney, et al.
Annals of Hematology|June 9, 2023
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphomaVictoria R Nachar, Anthony J Perissinotti, Bernard L Marini, et al.
JCO Clinical Cancer Informatics|April 30, 2021
Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record DataYasmin H Karimi, Douglas W Blayney, Allison W Kurian, et al.
Leukemia & Lymphoma|June 9, 2025
Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphomaMeng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips, et al.
Blood Advances|April 4, 2023
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphomaTycel J Phillips, David Bond, Radihka Takiar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative AnalysisJavier Munoz, Allison Rosenthal, Andrew Ip, et al.
Blood|January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialJoshua D Brody, Judit Jørgensen, David Belada, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Pageof 2